Clinical trial
Exatecan Mesylate in Treating Children With Relapsed or Refractory…
NCT00055939 · Daiichi Sankyo, Industry · Completed
Key facts
| NCT number | NCT00055939 |
|---|---|
| Title | Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma |
| Official title | A Phase II Study Of Intravenous DX-8951f (EXATECAN MESYLATE) Administered Daily For Five Days Every Three Weeks To Pediatric Patients With Relapsed Or Refractory Rhabdomyosarcoma |
| Lead sponsor | Daiichi Sankyo, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Drug |
| Interventions | exatecan mesylate |
| Start date | Jan 1, 2003 |
| Primary completion | Apr 1, 2006 |
| Completion | Apr 1, 2006 |
| First posted | Mar 7, 2003 |
| Last update posted | May 16, 2012 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: